- ICH GCP
- US Clinical Trials Registry
- Search trials
Clinical Trials on Hormone Sensitive Resected Primary Breast Cancer in Postmenopausal Women
Total 897 results
-
Novartis PharmaceuticalsUniversity of Sheffield; Danish Breast Cancer Cooperative GroupCompletedHormone Sensitive Resected Primary Breast Cancer in Postmenopausal WomenDenmark, United Kingdom
-
AstraZenecaCompletedPostmenopausal Women With ER+ HER2- Primary Breast CancerGermany, United Kingdom
-
Novartis PharmaceuticalsTerminatedPrimary Hormone Receptor Negative Breast Cancer in Premenopausal WomenGermany
-
University of MichiganMichigan Department of Community HealthCompletedBreast Cancer | Breast Cancer in Young Women | Breast Cancer in Women With a Strong Family HistoryUnited States
-
Novartis PharmaceuticalsChugai PharmaceuticalCompletedPostmenopausal Women With Advanced Breast CancerJapan
-
Novartis PharmaceuticalsChugai PharmaceuticalCompletedPostmenopausal Women With Advanced Breast CancerJapan
-
Novartis PharmaceuticalsChugai PharmaceuticalCompletedPostmenopausal Women With Advanced Breast CancerJapan
-
Novartis PharmaceuticalsCompletedMetastatic Breast Cancer | Postmenopausal Women | Locally Advanced Metastatic Breast CancerIsrael
-
Vanderbilt-Ingram Cancer CenterTerminatedEndocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast CancerHormone-sensitive Metastatic Breast CancerUnited States
-
MedImmune LLCCompletedHormone-sensitive, HER-2 Negative Metastatic Breast CancerSpain, United States, Belgium, France, United Kingdom, Canada, Israel, Germany, Hungary, Poland, Bahamas
-
Azienda U.S.L. 1 di Massa e CarraraCompletedBreast Cancer in Women Under 40 Years Old
-
Yale UniversityNovartis; Genentech, Inc.TerminatedBreast Cancer | Hormone-Sensitive Breast CancerUnited States
-
Istituto Scientifico Romagnolo per lo Studio e...Completed
-
BayerActive, not recruitingHot Flashes | Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast CancerSpain, France, Belgium, United Kingdom, Hungary, Israel, Italy, Ireland, Germany, Portugal, Finland, Poland, Romania, Canada, Austria, Kazakhstan
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)WithdrawnStage 0 Breast Cancer | Invasive Breast Carcinoma | Stage IA Breast Cancer | HER2/Neu Negative | PostmenopausalUnited States
-
Rhizen Pharmaceuticals SAActive, not recruitingSolid Tumor | Metastatic Breast Cancer | Locally Advanced Breast Cancer | Extensive-stage Small-cell Lung Cancer | Platinum-Sensitive Fallopian Tube Carcinoma | Platinum-sensitive Ovarian Cancer | Platinum-Sensitive Peritoneal CancerCzechia, Poland
-
AstraZenecaParexelCompletedHealthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer)Germany
-
Marmara UniversityNot yet recruitingBreast Cancer Awareness and BSE in Visually Impaired WomenTurkey
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)CompletedInvasive Breast Carcinoma | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Estrogen Receptor Negative | Estrogen Receptor Positive | Lobular Breast Carcinoma | Postmenopausal | Ductal Breast Carcinoma | Ductal Breast Carcinoma In SituUnited States
-
The First Affiliated Hospital with Nanjing Medical...RecruitingMetastatic Hormone-Sensitive Prostate Cancer (mHSPC)China
-
Fondazione IRCCS Istituto Nazionale dei Tumori,...European Institute of Oncology; ASST Santi Paolo e CarloRecruitingMetastatic Hormone-Sensitive Prostate Cancer (mHSPC)Italy
-
Alexandru EniuIuliu Hatieganu University of Medicine and PharmacyCompletedTo Determine the Prevalence, Penetrance of BRCA1 and BRCA2 Mutations in Romanian Womens With Breast or Ovarian CancerRomania
-
Institut fuer FrauengesundheitNovartis; ClinSolUnknownis to Identify Biomarkers That Could Predict the Efficacy of an Adjuvant Letrozol Treatment in Postmenopausal Breast Cancer Patients.Germany
-
German Cancer Research CenterCompletedInflammation | Breast Cancer | Lifestyle | Hormone Therapy | Breast Cancer Mortality | Inflammatory Biomarkers | Breast Cancer Survival | Postmenopausal Breast Cancer | Genetic Factors | Phytoestrogens
-
University of SaskatchewanSanofiTerminatedPlatinum Sensitive Relapsed Ovarian CancerCanada
-
Karolinska InstitutetCompletedWomen With Mutations in the Breast Cancer Susceptibility Genes BRCA1,2Sweden
-
UNICANCERRecruitingOligometastatic Hormone Sensitive Prostate CancerFrance, Martinique
-
Spanish Oncology Genito-Urinary GroupBristol-Myers Squibb; Syntax for Science, S.LActive, not recruitingMetastatic Hormone-sensitive Prostate CancerSpain
-
Washington University School of MedicineBristol-Myers Squibb; The Foundation for Barnes-Jewish Hospital; Bavarian Nordic and other collaboratorsCompletedMetastatic Hormone-Sensitive Prostate CancerUnited States
-
Peng Wang, MD PhDWithdrawnMetastatic Hormone-Sensitive Prostate CancerUnited States
-
Azienda Ospedaliero-Universitaria CareggiNot yet recruitingOligometastatic Hormone Sensitive Prostate CancerItaly
-
Astellas Pharma Global Development, Inc.CompletedProstate Cancer | Metastatic Hormone-sensitive Prostate CancerUnited States
-
Dr. Patrick CheungWithdrawnHormone Sensitive Oligometastatic Prostate CancerCanada
-
University of AarhusRanders Regional HospitalRecruitingCervix Cancer | Postmenopausal Women | HPV TestingDenmark
-
BayerCompletedVasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and MenUnited States
-
NRG OncologyNational Cancer Institute (NCI)Active, not recruitingAnatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Bone | Metastatic Malignant Neoplasm in the Lymph Nodes | Metastatic Malignant Neoplasm in the Liver | Metastatic Breast Carcinoma | Metastatic Malignant Neoplasm in the Lung and other conditionsUnited States, Canada, Saudi Arabia, Korea, Republic of
-
Thomas Jefferson UniversityNational Cancer Institute (NCI)SuspendedAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Invasive Breast Carcinoma | Hormone Receptor Positive Breast Carcinoma | Breast Ductal Carcinoma in Situ | HER2 Negative Breast CarcinomaUnited States
-
Jiangsu HengRui Medicine Co., Ltd.CompletedHormone Sensitive Prostate CancerChina
-
Ohio State University Comprehensive Cancer CenterCompletedDuctal Breast Carcinoma in Situ | Breast Cancer, Stage I | Breast Cancer, Stage II | Breast Cancer, Stage IIIUnited States
-
Royal Marsden NHS Foundation TrustJanssen, LPRecruitingMetastatic Hormone-Sensitive Prostate Cancer (mHSPC)United Kingdom
-
Jena University HospitalBayerRecruitingMetastatic Hormone-Sensitive Prostate Cancer (mHSPC)Germany
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)Active, not recruitingMetastatic Hormone-sensitive Prostate CancerUnited States
-
Astellas Pharma China, Inc.Active, not recruitingMetastatic Hormone Sensitive Prostate CancerChina
-
The First Affiliated Hospital with Nanjing Medical...RecruitingChemotherapy Effect | Metastatic Prostate Cancer | Hormone Sensitive Prostate CancerChina
-
Mayo ClinicRecruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage 0 Breast Cancer AJCC v8 | Hormone Receptor-Positive Breast CarcinomaUnited States
-
Mansoura UniversityCompletedthe Efficacy of Aromatase Inhibitor vs. Gonadotrpins Releasing Hormone Agonists in Treating Premenopausal Women With Uterine AdenomyosisEgypt
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...RecruitingChemotherapy Effect | DNA Damage Repair Deficiency | Chemotherapeutic Toxicity | Hormone Sensitive Metastatic Prostate CancerChina
-
AstraZenecaActive, not recruitingHormone-Sensitive Prostate CancerUnited States, Belgium, Spain, Canada, Poland, Argentina, India, Taiwan, Thailand, Vietnam, Turkey, Russian Federation, France, Germany, Korea, Republic of, Brazil, Mexico, Peru, Philippines, China, United Kingdom, Hong Kong, Israel, ... and more
-
Queen Mary University of LondonCompletedThe Initial Aim of This Project is to Perform in Vitro Validation of Neoepitope Candidates Selected From Available Mutanome DataUnited Kingdom
-
Prof. W. JanniActive, not recruitingHER2-negative and Hormone-receptor Positive Metastatic Breast Cancer | HER2-negative Circulating Tumor Cells | Postmenopausal Female PatientsGermany